What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Eculizumab for hyperhemolysis syndrome in sickle cell disease: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

MSMoazzam ShahzadUniversity of South Florida

Discussion

Member takes

Implication

Systematic review highlights Eculizumab improves outcomes in sickle cell disease patients with hyperhemolysis, suggesting effective intervention strategies.

Key Points

Eculizumab treatment led to a 93% resolution rate of hyperhemolysis syndrome.
Patients showed a median hemoglobin level of 4.2 g/dL prior to treatment with Eculizumab.
Analysis included outcomes from 11 studies focusing on sickle cell disease patients with hyperhemolysis syndrome.
Eculizumab may improve patient management in hyperhemolysis syndrome, though more high-quality studies are needed.

Cite This Study

Moazzam Shahzad (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2d7 https://doi.org/10.1182/blood-2025-6501

View Full Paper

Ask AI

Bookmark

Implication

Systematic review highlights Eculizumab improves outcomes in sickle cell disease patients with hyperhemolysis, suggesting effective intervention strategies.